Eterus Capital and Ethernum Capital have partnered to consolidate the Slovak pharmacy market
August 2024 — Eterus Capital has acquired a majority stake in EC Pharmacies, a consolidation platform established in partnership with Ethernum Capital.
Eterus Capital is a private equity fund founded in 2008, specializing in supporting small and medium-sized enterprises with proven business models and growth potential. The fund focuses on minority investments, ensuring management control remains with the original shareholders. Over the years, Eterus Capital has provided more than US$41 million (€40 million) in funding to over 20 companies. Its portfolio includes prominent brands such as Sygic, HOPIN, eyerim, Saneca Pharmaceuticals, Groupsolver and MTBIKER.
EC Pharmacies is a joint venture between Eterus Capital and Ethernum Capital, established to consolidate the Slovak pharmacy market through a "buy-and-build" strategy. The objective is to acquire 25–50 targeted pharmacies, improve operational performance, centralize marketing and supply chains and ultimately sell the established network to a strategic partner. Since its inception, EC Pharmacies has acquired nine pharmacies with an estimated annual portfolio revenue of US$6.2 million (€6 million). The company plans to expand its network by launching and acquiring additional operations in the near future, further strengthening its market presence.
Our role in the transaction
Oaklins’ team in Slovakia advised the buyer in this transaction.
Talk to the deal team
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Learn more